ducovest

A:NYE-Agilent Technologies Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 139.01

Change

+0.66 (+0.48)%

Market Cap

USD 39.94B

Volume

1.39M

Analyst Target

USD 102.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California. Address: 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.57 (-0.21%)

 USD 199.35B
IQV IQVIA Holdings Inc

+2.69 (+1.12%)

 USD 43.52B
LH Laboratory Corporation of Amer..

+0.21 (+0.09%)

 USD 18.96B
DGX Quest Diagnostics Incorporated

+0.10 (+0.06%)

 USD 17.18B
CRL Charles River Laboratories

-0.11 (-0.05%)

 USD 10.65B
QGEN Qiagen NV

+0.02 (+0.04%)

 USD 10.30B
VNRX Volitionrx Ltd

-0.05 (-7.58%)

 USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-0.89%)

 USD 0.06B
TMO Thermo Fisher Scientific Inc

-0.37 (-0.06%)

 N/A
MTD Mettler-Toledo International I..

+19.22 (+1.39%)

 N/A

ETFs Containing A

TECX:CA TD Global Technology Lead.. 97.96 % 0.00 %

-0.05 (1.44%)

 CAD 4.00M
TOCA:CA TD One-Click Aggressive E.. 16.24 % 0.00 %

N/A

 CAD 0.10B
TOCM:CA 14.25 % 0.00 %

N/A

 N/A
TOCC:CA 9.00 % 0.00 %

N/A

 N/A
HHL-U:CA Harvest Healthcare Leader.. 4.79 % 0.00 %

+0.01 (+1.44%)

 N/A
HHL-B:CA Harvest Healthcare Leader.. 4.79 % 0.00 %

+0.02 (+1.44%)

 N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.91 % 0.00 %

-0.22 (1.44%)

 N/A
EDOC Global X Telemedicine & D.. 3.88 % 0.00 %

-0.10 (1.44%)

 USD 0.04B
EDOG:LSE Global X Telemedicine & D.. 3.85 % 0.00 %

-0.10 (1.44%)

 USD 0.22M
XGES:LSE Xtrackers MSCI Genomic He.. 3.85 % 0.00 %

-0.26 (1.44%)

 N/A
EDOC:SW Global X Telemedicine & D.. 3.82 % 0.00 %

-0.10 (1.44%)

 N/A
EDOC:LSE Global X Telemedicine & D.. 3.75 % 0.00 %

-0.11 (1.44%)

 USD 3.75M
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

-0.08 (1.44%)

 N/A
ABIT:F AXA IM ACT Biodiversity E.. 2.32 % 0.00 %

+0.20 (+1.44%)

 N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.32 % 0.00 %

+0.18 (+1.44%)

 N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.19 % 0.00 %

-0.07 (1.44%)

 N/A
FIW First Trust Water ETF 0.00 % 0.55 %

-0.09 (1.44%)

 N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.02 (+1.44%)

 CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

 N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-7.25 (1.44%)

 N/A
MJJ 0.00 % 0.00 %

N/A

 N/A
MJO 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.01% 38% F 26% F
Dividend Return 0.34% 57% F 6% D-
Total Return 0.33% 31% F 23% F
Trailing 12 Months  
Capital Gain 23.60% 85% B 74% C
Dividend Return 0.83% 57% F 10% F
Total Return 24.43% 92% A 70% C-
Trailing 5 Years  
Capital Gain 78.29% 75% C 81% B-
Dividend Return 5.27% 80% B- 16% F
Total Return 83.56% 75% C 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 15.56% 85% B 79% B-
Dividend Return 16.26% 85% B 77% C+
Total Return 0.70% 86% B+ 16% F
Risk Return Profile  
Volatility (Standard Deviation) 29.56% 46% F 35% F
Risk Adjusted Return 54.99% 92% A 73% C
Market Capitalization 39.94B 78% C+ 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector